Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

The use of Trichomonas vaginalis purine nucleoside phosphorylase to activate fludarabine in the treatment of solid tumors.

Parker WB, Allan PW, Waud WR, Hong J, Gilbert-Ross M, Achyut BR, Joshi D, Behbahani T, Rab R, Ealick SE, Sorscher EJ.

Cancer Chemother Pharmacol. 2020 Jan 8. doi: 10.1007/s00280-019-04018-7. [Epub ahead of print]

PMID:
31915968
2.

6-Methylpurine derived sugar modified nucleosides: Synthesis and evaluation of their substrate activity with purine nucleoside phosphorylases.

Hassan AE, Abou-Elkhair RA, Parker WB, Allan PW, Secrist JA 3rd.

Bioorg Chem. 2016 Apr;65:9-16. doi: 10.1016/j.bioorg.2015.12.006. Epub 2015 Dec 24.

PMID:
26745284
3.

6-Methylpurine derived sugar modified nucleosides: Synthesis and in vivo antitumor activity in D54 tumor expressing M64V-Escherichia coli purine nucleoside phosphorylase.

Hassan AEA, Abou-Elkhair RAI, Parker WB, Allan PW, Secrist JA 3rd.

Eur J Med Chem. 2016 Jan 27;108:616-622. doi: 10.1016/j.ejmech.2015.12.029. Epub 2015 Dec 17.

PMID:
26724729
4.

Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.

Rosenthal EL, Chung TK, Parker WB, Allan PW, Clemons L, Lowman D, Hong J, Hunt FR, Richman J, Conry RM, Mannion K, Carroll WR, Nabell L, Sorscher EJ.

Ann Oncol. 2015 Jul;26(7):1481-7. doi: 10.1093/annonc/mdv196. Epub 2015 Apr 21.

5.

Role of methylthioadenosine/S-adenosylhomocysteine nucleosidase in Vibrio cholerae cellular communication and biofilm development.

Silva AJ, Parker WB, Allan PW, Ayala JC, Benitez JA.

Biochem Biophys Res Commun. 2015 May 22;461(1):65-9. doi: 10.1016/j.bbrc.2015.03.170. Epub 2015 Apr 4.

6.

Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidine.

Thottassery JV, Sambandam V, Allan PW, Maddry JA, Maxuitenko YY, Tiwari K, Hollingshead M, Parker WB.

Cancer Chemother Pharmacol. 2014 Aug;74(2):291-302. doi: 10.1007/s00280-014-2503-z. Epub 2014 Jun 8.

7.

In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.

Sorscher EJ, Hong JS, Allan PW, Waud WR, Parker WB.

Cancer Chemother Pharmacol. 2012 Aug;70(2):321-9. doi: 10.1007/s00280-012-1908-9. Epub 2012 Jul 4.

8.

Synthesis and evaluation of the substrate activity of C-6 substituted purine ribosides with E. coli purine nucleoside phosphorylase: palladium mediated cross-coupling of organozinc halides with 6-chloropurine nucleosides.

Hassan AE, Abou-Elkhair RA, Riordan JM, Allan PW, Parker WB, Khare R, Waud WR, Montgomery JA, Secrist JA 3rd.

Eur J Med Chem. 2012 Jan;47(1):167-74. doi: 10.1016/j.ejmech.2011.10.039. Epub 2011 Nov 4.

9.

The crystal structure of Streptococcus pyogenes uridine phosphorylase reveals a distinct subfamily of nucleoside phosphorylases.

Tran TH, Christoffersen S, Allan PW, Parker WB, Piskur J, Serra I, Terreni M, Ealick SE.

Biochemistry. 2011 Aug 2;50(30):6549-58. doi: 10.1021/bi200707z. Epub 2011 Jul 8.

10.

Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase.

Parker WB, Allan PW, Waud WR, Hong JS, Sorscher EJ.

Cancer Gene Ther. 2011 Jun;18(6):390-8. doi: 10.1038/cgt.2011.4. Epub 2011 Mar 11.

11.

Regioselective metalation of 6-methylpurines: synthesis of fluoromethyl purines and related nucleosides for suicide gene therapy of cancer.

Hassan AE, Parker WB, Allan PW, Secrist JA 3rd.

Nucleosides Nucleotides Nucleic Acids. 2009 May;28(5):642-56. doi: 10.1080/15257770903091938.

PMID:
20183607
12.

Structure of grouper iridovirus purine nucleoside phosphorylase.

Kang YN, Zhang Y, Allan PW, Parker WB, Ting JW, Chang CY, Ealick SE.

Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):155-62. doi: 10.1107/S0907444909048276. Epub 2010 Jan 22.

13.

Evaluation of 3-deaza-adenosine analogues as ligands for adenosine kinase and inhibitors of Mycobacterium tuberculosis growth.

Long MC, Allan PW, Luo MZ, Liu MC, Sartorelli AC, Parker WB.

J Antimicrob Chemother. 2007 Jan;59(1):118-21. Epub 2006 Nov 3.

PMID:
17085766
14.

Synthesis and biological activity of 2-fluoro adenine and 6-methyl purine nucleoside analogs as prodrugs for suicide gene therapy of cancer.

Silamkoti AV, Allan PW, Hassan AE, Fowler AT, Sorscher EJ, Parker WB, Secrist JA 3rd.

Nucleosides Nucleotides Nucleic Acids. 2005;24(5-7):881-5.

PMID:
16248054
15.

Design and evaluation of 5'-modified nucleoside analogs as prodrugs for an E. coli purine nucleoside phosphorylase mutant.

Parker WB, Allan PW, Ealick SE, Sorscher EJ, Hassan AE, Silamkoti AV, Fowler AT, Waud WR, Secrist JA 3rd.

Nucleosides Nucleotides Nucleic Acids. 2005;24(5-7):387-92.

PMID:
16247956
16.

Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy.

Bharara S, Sorscher EJ, Gillespie GY, Lindsey JR, Hong JS, Curlee KV, Allan PW, Gadi VK, Alexander SA, Secrist JA 3rd, Parker WB, Waud WR.

Hum Gene Ther. 2005 Mar;16(3):339-47.

PMID:
15812229
17.

Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene.

Hong JS, Waud WR, Levasseur DN, Townes TM, Wen H, McPherson SA, Moore BA, Bebok Z, Allan PW, Secrist JA 3rd, Parker WB, Sorscher EJ.

Cancer Res. 2004 Sep 15;64(18):6610-5.

18.

Metabolism of 2-methyladenosine in Mycobacterium tuberculosis.

Parker WB, Barrow EW, Allan PW, Shaddix SC, Long MC, Barrow WW, Bansal N, Maddry JA.

Tuberculosis (Edinb). 2004;84(5):327-36.

PMID:
15207808
19.

Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system.

Bennett EM, Anand R, Allan PW, Hassan AE, Hong JS, Levasseur DN, McPherson DT, Parker WB, Secrist JA 3rd, Sorscher EJ, Townes TM, Waud WR, Ealick SE.

Chem Biol. 2003 Dec;10(12):1173-81.

PMID:
14700625
20.

Selective metalation of 6-methylpurines: synthesis of 6-fluoromethylpurines and related nucleosides.

Hassan AE, Parker WB, Allan PW, Montgomery JA, Secrist JA 3rd.

Nucleosides Nucleotides Nucleic Acids. 2003 May-Aug;22(5-8):747-9.

PMID:
14565269
21.

Structural basis for substrate specificity of Escherichia coli purine nucleoside phosphorylase.

Bennett EM, Li C, Allan PW, Parker WB, Ealick SE.

J Biol Chem. 2003 Nov 21;278(47):47110-8. Epub 2003 Aug 21.

22.

A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration.

Gadi VK, Alexander SD, Waud WR, Allan PW, Parker WB, Sorscher EJ.

J Pharmacol Exp Ther. 2003 Mar;304(3):1280-4.

PMID:
12604707
23.

Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase.

Parker WB, Allan PW, Hassan AE, Secrist JA 3rd, Sorscher EJ, Waud WR.

Cancer Gene Ther. 2003 Jan;10(1):23-9.

PMID:
12489025
24.

The metabolism of 2-methyladenosine in Mycobacterium smegmatis.

Chen CK, Barrow EW, Allan PW, Bansal N, Maddry JA, Suling WJ, Barrow WW, Parker WB.

Microbiology. 2002 Jan;148(Pt 1):289-295. doi: 10.1099/00221287-148-1-289.

PMID:
11782521
25.

Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase.

Secrist JA 3rd, Parker WB, Allan PW, Bennett LL Jr, Waud WR, Truss JW, Fowler AT, Montgomery JA, Ealick SE, Wells AH, Gillespie GY, Gadi VK, Sorscher EJ.

Nucleosides Nucleotides. 1999 Apr-May;18(4-5):745-57.

PMID:
10432677
26.

Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells.

Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY, Bennett LL Jr.

Biochem Pharmacol. 1998 May 15;55(10):1673-81.

PMID:
9634004
27.
28.

Polyamine pools in HIV-infected cells.

White EL, Rose LM, Allan PW, Buckheit RW Jr, Shannon WM, Secrist JA 3rd.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Feb 1;17(2):101-3.

PMID:
9473009
29.

Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase.

Hughes BW, King SA, Allan PW, Parker WB, Sorscher EJ.

J Biol Chem. 1998 Jan 23;273(4):2322-8.

30.

Toxicity of cordycepin in combination with the adenosine deaminase inhibitor 2'-deoxycoformycin in beagle dogs.

Rodman LE, Farnell DR, Coyne JM, Allan PW, Hill DL, Duncan KL, Tomaszewski JE, Smith AC, Page JG.

Toxicol Appl Pharmacol. 1997 Nov;147(1):39-45.

PMID:
9356305
31.

In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase.

Parker WB, King SA, Allan PW, Bennett LL Jr, Secrist JA 3rd, Montgomery JA, Gilbert KS, Waud WR, Wells AH, Gillespie GY, Sorscher EJ.

Hum Gene Ther. 1997 Sep 20;8(14):1637-44.

PMID:
9322865
32.

Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines.

Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL Jr, Parker WB.

Gene Ther. 1994 Jul;1(4):233-8.

PMID:
7584086
33.
34.

Phosphorylation of the enantiomers of the carbocyclic analog of 2'-deoxyguanosine in cells infected with herpes simplex virus type 1 and in uninfected cells. Lack of enantiomeric selectivity with the viral thymidine kinase.

Bennett LL Jr, Parker WB, Allan PW, Rose LM, Shealy YF, Secrist JA 3rd, Montgomery JA, Arnett G, Kirkman RL, Shannon WM.

Mol Pharmacol. 1993 Dec;44(6):1258-66.

PMID:
8264563
35.

Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds.

Bennett LL Jr, Allan PW, Noker PE, Rose LM, Niwas S, Montgomery JA, Erion MD.

J Pharmacol Exp Ther. 1993 Aug;266(2):707-14.

PMID:
8355201
36.

Incorporation of the carbocyclic analog of 2'-deoxyguanosine into the DNA of herpes simplex virus and of HEp-2 cells infected with herpes simplex virus.

Parker WB, Shaddix SC, Allan PW, Arnett G, Rose LM, Shannon WM, Shealy YF, Montgomery JA, Secrist JA 3rd, Bennett LL Jr.

Mol Pharmacol. 1992 Feb;41(2):245-51.

PMID:
1311407
37.

Phosphorylation of the carbocyclic analog of 2'-deoxyguanosine in cells infected with herpes viruses.

Bennett LL Jr, Shealy YF, Allan PW, Rose LM, Shannon WM, Arnett G.

Biochem Pharmacol. 1990 Oct 1;40(7):1515-22.

PMID:
2171531
38.

Alterations in nucleotide pools induced by 3-deazaadenosine and related compounds. Role of adenylate deaminase.

Bennett LL Jr, Brockman RW, Allan PW, Rose LM, Shaddix SC.

Biochem Pharmacol. 1988 Apr 1;37(7):1233-44.

PMID:
3355597
39.

Evidence that the carbocyclic analog of adenosine has different mechanisms of cytotoxicity to cells with adenosine kinase activity and to cells lacking this enzyme.

Bennett LL Jr, Bowdon BJ, Allan PW, Rose LM.

Biochem Pharmacol. 1986 Nov 15;35(22):4106-9. No abstract available.

PMID:
3022752
40.

Synthesis and biochemical properties of 8-amino-6-fluoro-9-beta-D-ribofuranosyl-9H-purine.

Secrist JA 3rd, Bennett LL Jr, Allan PW, Rose LM, Chang CH, Montgomery JA.

J Med Chem. 1986 Oct;29(10):2069-74.

PMID:
3489838
41.

Differences in the metabolism and metabolic effects of the carbocyclic adenosine analogs, neplanocin A and aristeromycin.

Bennett LL Jr, Allan PW, Rose LM, Comber RN, Secrist JA 3rd.

Mol Pharmacol. 1986 Apr;29(4):383-90.

PMID:
3702857
43.

Phosphorylation of "tricyclic nucleoside" by adenosine kinases from L1210 cells and HEp-2 cells.

Bennett LL Jr, Allan PW, Chang CH.

Biochem Pharmacol. 1983 Sep 1;32(17):2601-2. No abstract available.

PMID:
6311222
44.

Biological activities and modes of action of 9-alpha-D-arabinofuranosyladenine and 9-alpha-D-arabinofuranosyl-8-azaadenine.

Bennett LL Jr, Allan PW, Shaddix SC, Shannon WM, Arnett G, Westbrook L, Drach JC, Reinke CM.

Biochem Pharmacol. 1981 Aug 15;30(16):2325-32. No abstract available.

45.

The philosophy of an institutional review board for the protection of human subjects.

Brown JH, Schoenfeld LS, Allan PW.

J Med Educ. 1980 Jan;55(1):67-9. No abstract available.

PMID:
7351667
46.

Metabolism and metabolic effects of 8-aza-6-thioinosine and its rearrangement product, N-beta-D-ribofuranosyl-[1,2,3]thiadiazolo[5,4-d]-pyrimidin-7-amine.

Bennett LL Jr, Rose LM, Allan PW, Smithers D, Adamson DJ, Elliott RD, Montgomery JA.

Mol Pharmacol. 1979 Nov;16(3):981-96. No abstract available.

PMID:
119157
47.

The costs of an institutional review board.

Brown JH, Schoenfeld LS, Allan PW.

J Med Educ. 1979 Apr;54(4):294-9.

PMID:
430531
48.

Substrate activities for adenosine kinase and adenosine deaminase in relation to the cytotoxicities of some O6-alkyl derivatives of 8-azainosine and 8-azaguanosine.

Bennett LL Jr, Allan PW, Elliott RD, Montgomery JA.

Biochem Pharmacol. 1979 Mar 15;28(6):946-8. No abstract available.

PMID:
222297
49.

Metabolism and mechanism of action of some new purine antimetabolites.

Montgomery JA, Elliott RD, Allan PW, Rose LM, Bennett LL Jr.

Adv Enzyme Regul. 1978;17:419-35. No abstract available.

PMID:
575020
50.

Inosine analogs as substrates for adenosine kinase--influence of ionization of the N-1 proton on the rate of phosphorylation.

Bennet LL Jr, Hill DL, Allan PW.

Biochem Pharmacol. 1978 Jan 1;27(1):83-7. No abstract available.

PMID:
23125

Supplemental Content

Loading ...
Support Center